Gravity Analytica

MiNK Therapeutics Announces Appointment of Dr. Robert Kadlec to Board of Directors

INKT 10.31.2024

Full Press Release SEC Filings Our INKT Tweets

About Gravity Analytica

Recent Filings

NEW YORK,Oct. 31, 2024(GLOBE NEWSWIRE) --MiNK Therapeutics(MiNK, NASDAQ: INKT), a clinical-stage company pioneering the development of allogeneic off-the-shelf, invariant natural killer T (iNKT) cell therapies, today announced the appointment of Dr.Robert Kadlecto its Board of Directors.Dr. Kadlecbrings unparalleled expertise in biodefense, pandemic preparedness, and public health strategy, positioning MiNK to accelerate its innovative iNKT cell platform for addressing critical infectious diseases, including pathogen-agnostic acute respiratory distress syndrome (ARDS), emerging threats, and immune related diseases.

Dr. Kadlecrecently served as theU.S. Senate-confirmed Assistant Secretary for Preparedness and Response (ASPR) at theU.S. Department of Health and Human Services(HHS) where he led interagency responses to public health emergencies and natural disasters. During the COVID-19 pandemic,Dr. Kadlecco-conceived and initiated the vaccine program known as Operation Warp Speed and directed the pandemic response on behalf of HHS. A retired careerAir Forceofficer and physician, he earlier served senior roles in theWhite House,U.S. Senate, andDepartment of Defense. His prior roles as Deputy Staff Director for theSenate Select Committee on Intelligenceand his work on the Pandemic and All-Hazards Preparedness Act and PREVENT Pandemics Act exemplify his commitment to advancingU.S.health security.Dr. Kadlecpreviously directed the biodefense strategy at theWhite House, leading initiatives that shaped national policy for public health emergencies.

“We are thrilled to welcomeDr. Kadlecto our Board of Directors,” saidJennifer Buell, PhD, Chief Executive Officer and President ofMiNK Therapeutics. “As we continue to demonstrate the transformative potential of iNKT cells as a pathogen-agnostic approach to ARDS and other immune-related conditions, Dr. Kadlec’s unparalleled expertise in public health and biodefense will be instrumental in advancing our strategic vision. His deep understanding of public health systems, coupled with his proven track record of driving innovation in medical countermeasures, makes him the ideal partner to guide MiNK through our next phase of growth. Together, we aim to harness the power of iNKT cells to address some of the most urgent challenges in global health.”

Dr. Kadlecholds a bachelor’s degree from theUnited States Air Force Academy, a Doctor of Medicine and a master’s degree in tropical medicine and hygiene from theUniformed Services Universityof the Health Sciences, as well as a master’s degree in national security studies fromGeorgetown University.

AboutMiNK Therapeutics

MiNK Therapeuticsis a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. MiNK is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery. The company is headquartered inNew York, NY. For more information, visithttps://minktherapeutics.com/or @MiNK_iNKT. Information that may be important to investors will be routinely posted on our website and social media channels.

Forward Looking Statements

This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding the therapeutic potential, anticipated benefit, plans and timelines of iNKT cells and encrypted RNA, as well as the collaboration between MiNK and Autonomous Therapeutics. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These forward-looking statements are subject to risks and uncertainties, including the factors described under the Risk Factors section of the most recent Form 10-K, Form 10-Q and the S-1 Registration Statement filed with theSEC. MiNK cautions investors not to place considerable reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this press release, and MiNK and Autonomous undertake no obligation to update or revise the statements, other than to the extent required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.

Investor Contact

917-362-1370

investor@minktherapeutics.com

Media Contact

781-674-4428

communications@minktherapeutics.com

Source: MiNK Therapeutics

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com

MiNK Therapeutics Announces Appointment of Dr. Robert Kadlec to Board of Directors

INKT 10.31.2024

About Gravity Analytica

Recent News

Recent Filings